Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ptc Therapeutics (NQ: PTCT )

51.86 -1.06 (-2.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 563,170
Open 53.07
Bid (Size) 51.86 (46)
Ask (Size) 51.93 (7)
Prev. Close 52.92
Today's Range 51.36 - 53.40
52wk Range 25.01 - 54.46
Shares Outstanding 71,540,965
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
PTC Therapeutics: Q2 Earnings Insights
PTC Therapeutics (NASDAQ:PTCT) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
+22.10%
+22.10%
1 Month
+19.47%
+19.47%
3 Month
+62.83%
+62.83%
6 Month
+25.84%
+25.84%
1 Year
+34.91%
+34.91%

More News

Read More
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
Via Benzinga
Raymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's Next
Via Benzinga
Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder
Via Benzinga
PTC Stock Has Gained 27% This Week Alone, And It's Still Sprinting
Via Investor's Business Daily
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Earnings Scheduled For February 22, 2022
Via Benzinga
Earnings Scheduled For October 28, 2021
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
PTC Therapeutics's Return On Capital Employed Overview
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
Via Benzinga
Earnings Scheduled For May 3, 2022
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
Recap: PTC Therapeutics Q4 Earnings
Via Benzinga
PTC Therapeutics Inc (PTCT) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.